INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in the development and commercialization of graphene-based neural interfaces and intelligent neuromodulation systems. Their mission is to improve people's lives by creating innovative neuroelectronic therapies that solve the "neural challenge," which refers to the global impact of neural disorders. The company is driven by its belief in the power of graphene, a strong and conductive material, to revolutionize the treatment of neural conditions like Parkinson's disease, epilepsy, and speech impairment.

INBRAIN's technology is built on a unique, end-to-end neural platform that combines hardware and data analytics to decode and modulate neural networks, maximize time on therapy, and effectively restore function or mobility for patients. Their approach focuses on creating high-resolution, minimally invasive brain-computer interfaces (BCIs) that can be upgraded wirelessly and personalized to individual patient needs. InBRAIN has received FDA Breakthrough Device Designation for its platform's use in Parkinson's Disease, demonstrating the company's commitment to developing cutting-edge therapies with significant potential to improve patient outcomes.

INBRAIN Neuroelectronics is a Spanish medical device company dedicated to developing breakthrough neuroelectronic therapies for patients suffering from neural disorders. Their mission is to improve lives by inventing graphene-based, intelligent neural systems that decode and modulate neural activity with unprecedented precision and efficiency. By harnessing the power of graphene, INBRAIN aims to create high-resolution brain-computer interfaces (BCIs) and bioelectronic therapies that offer a personalized approach to treatment, maximizing time on therapy and restoring function or mobility for patients.

Inbrain Neuroelectronics fosters a collaborative and innovative culture, welcoming a diverse team of highly experienced materials and neurotech experts from 14 different countries. The company emphasizes a strong belief in the potential of graphene technology to revolutionize neural disorder treatment, attracting individuals who are passionate about contributing to groundbreaking solutions for improving lives. The company's leadership and advisory board showcase a commitment to a forward-thinking and collaborative approach, valuing scientific and clinical expertise while fostering a supportive environment for professional growth.